Ionis Pharmaceuticals (MEX:IONS) Short-Term Debt: MXN7,799 Mil (As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
72 GF Score
Price MXN1,150.00
GF Value MXN1,062.74
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Short-Term Debt?

Ionis Pharmaceuticals MEX:IONS 72 Short-Term Debt is MXN7,799 Mil as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 72/100 and a GF Value™ of MXN1,062.74. The stock has 6 warning signs investors should review.

Ionis Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2026 was MXN7,799 Mil.

Ionis Pharmaceuticals's quarterly Short-Term Debt declined from Sep. 2025 (MXN11,574 Mil) to Dec. 2025 (MXN8,187 Mil) and declined from Dec. 2025 (MXN8,187 Mil) to Mar. 2026 (MXN7,799 Mil).

Ionis Pharmaceuticals's annual Short-Term Debt declined from Dec. 2023 (MXN902 Mil) to Dec. 2024 (MXN194 Mil) but then increased from Dec. 2024 (MXN194 Mil) to Dec. 2025 (MXN8,187 Mil).

Ionis Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Ionis Pharmaceuticals Short-Term Debt Related Terms

Ionis Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Short-Term Debt Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.33 146.90 902.40 193.52 8,186.94

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 11,864.62 11,573.56 8,186.94 7,799.14
MEX:IONS
72GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of MXN7,799 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Short-Term Debt of MXN7,799 Mil as of Mar. 2026.
Is Ionis Pharmaceuticals' Short-Term Debt too high?
Ionis Pharmaceuticals' current Short-Term Debt is MXN7,799 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Short-Term Debt compare to EXEL and BBIO?
Ionis Pharmaceuticals' Short-Term Debt of MXN7,799 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Ionis Pharmaceuticals's current Short-Term Debt is MXN7,799 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Short-Term Debt of MXN7,799 Mil. The stock's GF Value™ is MXN1,062.74, compared to a current price of MXN1,150.00 — trading 8.2% above its estimated fair value. The current Short-Term Debt is MXN7,799 Mil. Ionis Pharmaceuticals' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Short-Term Debt is MXN7,799 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 8.2% above its estimated GF Value™ of MXN1,062.74.

Key valuation signals for MEX:IONS:

  • Short-Term Debt: MXN7,799 Mil
  • GF Value™: MXN1,062.74 vs. price of MXN1,150.00 (8.2% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
72GF Score

Get the complete analysis for MEX:IONS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN1,062.74
GF Value